H Joachim Deeg Selected Research

Myelodysplastic Syndromes (Myelodysplastic Syndrome)

12/2022	Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.
1/2022	NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
1/2021	Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
1/2021	Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome.
12/2019	The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.
1/2019	Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.
1/2019	Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms.
1/2018	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.
9/2017	Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
4/2017	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

H Joachim Deeg Research Topics

Disease

76	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2022 - 01/2002
42	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 01/2002
26	Neoplasms (Cancer) 01/2022 - 07/2002
25	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2022 - 01/2002
21	Primary Myelofibrosis (Myelosclerosis) 12/2020 - 08/2002
16	Aplastic Anemia (Anemia, Hypoplastic) 01/2019 - 07/2005
12	Hematologic Neoplasms (Hematological Malignancy) 11/2020 - 05/2005
10	Leukemia 12/2020 - 10/2003
8	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2020 - 09/2005
8	Bronchiolitis Obliterans Syndrome 01/2020 - 07/2002
6	Iron Overload 01/2016 - 11/2008
5	Chromosome Aberrations (Chromosome Abnormalities) 01/2021 - 08/2004
5	Essential Thrombocythemia 11/2015 - 07/2002
5	Polycythemia Vera 11/2015 - 07/2002
5	Myeloproliferative Disorders (Myeloproliferative Disorder) 11/2006 - 08/2002
4	Anemia 01/2017 - 01/2008
4	Refractory Anemia with Excess of Blasts (RAEM) 01/2008 - 11/2004
3	Renal Insufficiency (Renal Failure) 01/2020 - 10/2003
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2012 - 03/2011
3	Necrosis 06/2010 - 07/2002
2	Cytopenia 12/2016 - 03/2010
2	Systemic Mastocytosis 01/2016 - 10/2014
2	Bone Marrow Failure Disorders 10/2015 - 09/2004
2	Fanconi Anemia (Fanconi's Anemia) 10/2015 - 09/2004
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2010 - 08/2003
2	Basal Cell Carcinoma (Rodent Ulcer) 02/2009 - 03/2006
2	Liver Failure 08/2008 - 03/2004
2	Fibrosis (Cirrhosis) 03/2007 - 01/2006
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2006 - 05/2005
2	Refractory Anemia 12/2005 - 11/2004
1	Blast Crisis (Blast Phase) 11/2020
1	Jaundice (Icterus) 01/2020
1	Viremia 01/2020
1	Infections 01/2020
1	Bacteremia 01/2020
1	Weight Loss (Weight Reduction) 01/2019
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2019
1	Disease Progression 01/2017
1	Autoimmune Diseases (Autoimmune Disease) 01/2016
1	Hypoxia (Hypoxemia) 09/2015
1	Residual Neoplasm 02/2015

Drug/Important Bio-Agent (IBA)

10	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 08/2002
9	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2020 - 07/2002
7	Busulfan (Busulfex)FDA Link 01/2021 - 01/2002
7	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2017 - 11/2004
7	Methotrexate (Mexate)FDA LinkGeneric 12/2014 - 08/2003
6	Azacitidine (5 Azacytidine)FDA Link 12/2022 - 03/2010
6	fludarabineIBA 01/2018 - 12/2009
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2010 - 09/2004
5	Lenalidomide (CC 5013)FDA Link 01/2017 - 01/2008
5	SteroidsIBA 01/2016 - 01/2002
5	GlucocorticoidsIBA 01/2014 - 04/2002
4	Prednisone (Sone)FDA LinkGeneric 01/2020 - 07/2002
4	HLA Antigens (Human Leukocyte Antigens)IBA 01/2017 - 05/2003
4	Proteins (Proteins, Gene)FDA Link 05/2015 - 12/2005
4	AntigensIBA 09/2012 - 09/2005
4	IronIBA 01/2011 - 02/2009
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2009
3	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2020 - 07/2005
3	treosulfanIBA 01/2020 - 03/2011
3	Calcineurin InhibitorsIBA 01/2019 - 05/2008
3	thymoglobulin FDA Link 01/2017 - 05/2006
3	Tacrolimus (Prograf)FDA LinkGeneric 12/2014 - 05/2008
3	Etanercept (Enbrel)FDA Link 06/2010 - 11/2004
2	Indicators and Reagents (Reagents)IBA 01/2022 - 10/2008
2	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 01/2014
2	Histones (Histone)IBA 01/2014 - 01/2008
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2010 - 02/2010
2	Ferritins (Ferritin)IBA 10/2009 - 11/2008
2	LigandsIBA 01/2009 - 08/2003
2	TNF-Related Apoptosis-Inducing LigandIBA 12/2008 - 09/2004
2	Transferrin (beta 2 Transferrin)IBA 08/2008 - 03/2004
2	Caspase 8 (Caspase-8)IBA 09/2004 - 08/2003
1	eprenetapoptIBA 12/2022
1	Biological FactorsIBA 01/2022
1	H3B-8800IBA 12/2021
1	Core Binding Factors (Core-Binding Factor)IBA 01/2021
1	trans-crotonin (CTN)IBA 01/2021
1	ruxolitinibIBA 01/2020
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2019
1	CytosineIBA 01/2017
1	CateninsIBA 01/2017
1	A-Form DNA (A-DNA)IBA 01/2017
1	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 12/2016
1	Janus KinasesIBA 11/2015
1	HLA-A Antigens (HLA-A)IBA 09/2015

Therapy/Procedure

89	Cell Transplantation 01/2022 - 05/2003
50	Therapeutics 01/2022 - 01/2002
42	Transplantation 12/2020 - 01/2002
20	Hematopoietic Stem Cell Transplantation 12/2022 - 01/2002
8	Stem Cell Transplantation 05/2015 - 07/2002
7	Homologous Transplantation 01/2021 - 07/2005
6	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2017 - 03/2002
3	Artificial Respiration (Mechanical Ventilation) 01/2020 - 10/2003
3	Drug Therapy (Chemotherapy) 02/2015 - 12/2007
2	Aftercare (After-Treatment) 09/2017 - 03/2011
2	Erythrocyte Transfusion 10/2009 - 11/2008
2	Radiotherapy 02/2009 - 12/2007
1	Salvage Therapy 01/2016
1	Consolidation Chemotherapy 02/2015